Idec Zevalin

Idec agrees to market lymphoma radioimmunotherapy Zevalin (ibritumomab) in two kits - an imaging kit with indium and a therapeutic kit with yttrium - as requested in FDA "complete review" letter. Idec will also submit analyses of hospitalization and cytopenia seen in clinical trials, as well as manufacturing information. The company will respond to FDA in mid-July, Idec says. The BLA had a user fee action date of May 3